Search clinical trials for: bendamustine plus rituximab

Total 15542 results

The Lymphoma Academic Research Organisation
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea; Swiss Group... and other collaborators

Recruiting

Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5 (MorningLyte)

Follicular Lymphoma

Belgium, France, Germany, Portugal, Spain
Institute of Hematology & Blood Diseases Hospital

Recruiting

Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM (ZBR)

Waldenstrom Macroglobulinemia

China
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL (ZFCR/ZBR)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Newly Diagnosed

China
Miltenyi Biomedicine GmbH
ICON plc

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

Diffuse Large B-cell Lymphoma

Spain, Germany, Netherlands, Belgium, France, Czechia, Austria, Lithuania, Sweden, Hungary, Italy, Poland
Asan Medical Center
Cheolwon Suh

Recruiting

Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma (PTLD)

Diffuse Large B Cell Lymphoma

Korea, Republic of
National Cancer Institute (NCI)

Active, not recruiting

Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Canada
Acerta Pharma BV

Active, not recruiting

A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Chronic Lymphocytic Leukemia

Austria, Italy, Spain, United Kingdom, Belgium, Taiwan, France, Korea, Republic of, Hungary, United States, Ukraine, Canada, Australia, Germany, Israel, Czechia, Russian Federation, Slovakia, Poland, Bulgaria, New Zealand, Sweden, C... and more
Loxo Oncology, Inc.
Eli Lilly and Company

Active, not recruiting

A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) (BRUIN CLL-313)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China, Spain, Czechia, Taiwan, Italy, Japan, New Zealand, Poland, Hungary, United States, United Kingdom, Australia, Romania, Portugal, Korea, Republic of, Russian Federation, Austria, Brazil, Bulgaria, France, Ireland
The Lymphoma Academic Research Organisation
Celgene Corporation

Active, not recruiting

A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma (RELEVANCE)

Follicular Lymphoma

Spain, Canada, France, Australia, Italy, Belgium, Germany, Portugal
PrECOG, LLC.
Genentech, Inc.

Active, not recruiting

Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age (PrE0405)

Mantle Cell Lymphoma

United States
BeiGene

Active, not recruiting

A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL (SEQUOIA)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, China, Taiwan, Belgium, France, United Kingdom, Spain, New Zealand, Australia, Czechia, Italy, Poland, Russian Federation, Sweden, Austria
Hoffmann-La Roche
AbbVie

Completed

A Study to Evaluate the Benefit of Venetoclax Plus Rituximab Compared With Bendamustine Plus Rituximab in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) (MURANO)

Chronic Lymphocytic Leukemia

Hungary, Spain, France, United Kingdom, United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Germany, Italy, Korea, Republic of, Netherlands, New Zealand, Poland, Russian Federation, Sweden, Taiwan
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

CMC-544 and Allogeneic Transplantation for CD22 Positive-Lymphoid Malignancies

Hematopoietic and Lymphoid Cell Neoplasm

United States
Hoffmann-La Roche

Completed

A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Italy, Korea, Republic of, Australia, Canada, Czechia, Spain, United Kingdom, France, Germany, Hungary, Turkey, Netherlands
Hoffmann-La Roche
Institute of Cancer Research, United Kingdom; German Low Grade Lymphoma Study...

Completed

A Study of Obinutuzumab (RO5072759) Plus Chemotherapy in Comparison With Rituximab Plus Chemotherapy Followed by Obinutuzumab or Rituximab Maintenance in Patients With Untreated Advanced Indolent Non-Hodgkin's Lymphoma (GALLIUM)

Non-Hodgkin's Lymphoma

Italy, Belgium, Canada, United Kingdom, Australia, China, Germany, United States, Russian Federation, Spain, Taiwan, Israel, Czechia, Hungary, Japan, France, Finland, Sweden
Fondazione Italiana Linfomi ONLUS

Completed

Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL (FIL-RBAC500)

Mantle Cell Lymphoma

Italy
Celgene

Withdrawn

Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma

Lymphoma, B-Cell

Korea, Republic of, United States, Spain, Belgium, Taiwan, United Kingdom, Austria, France
Seoul National University Hospital
Chonbuk National University Hospital; Seoul National University Bundang Hospital and other collaborators

Completed

Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL)

Marginal Zone B-cell Lymphoma

Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)

Diffuse Large B-Cell Lymphoma, Lymphoma Follicular

United States, Australia, Italy
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Efficacy and Safety of Bendamustine Plus Rituximab in Chronic Lympocytic Leukemia (LLC1315)

Chronic Lymphocytic Leukemia

Italy
Samsung Medical Center

Unknown

Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)

Mantle Cell Lymphoma

Korea, Republic of
Hoffmann-La Roche
AbbVie

Completed

A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)

Follicular Lymphoma

United States, Italy, Canada, Australia, Belgium, United Kingdom, Germany, France
Pfizer
UCB Pharma

Terminated

A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Lymphoma, Non-Hodgkin

Canada, United States, Spain, France, Singapore, Taiwan, Japan, Ireland, Belgium, United Kingdom, Germany, Slovakia, Thailand, Croatia, Czechia, Russian Federation, India, Sweden, Poland, Bulgaria, Hungary, Lithuania, Mexico, Puerto Rico and more
Lund University Hospital
Mundipharma Pte Ltd.; Roche Pharma AG; Celgene

Completed

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma. (LENA-BERIT)

Mantle Cell Lymphoma

Finland, Denmark, Norway, Sweden
Massachusetts General Hospital
Dana-Farber Cancer Institute

Completed

Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLL

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | B Chronic Lymphocytic Leukemia

United States
Sanofi

Completed

Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Indolent Non-Hodgkin Lymphoma

United States
Fondazione Italiana Linfomi ONLUS

Unknown

Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL

Diffuse Large B-cell Lymphoma

Italy
University of Giessen

Completed

Bendamustine Plus Rituximab Versus Fludarabine Plus Rituximab

Non-Hodgkin's Lymphoma | Mantle Cell Lymphoma

Germany
University of Giessen

Completed

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Marginal Zone Lymphomas | Non-Hodgkin Lymphomas | Follicular Lymphomas | Immunocytomas | Lymphocytic Lymphomas

Germany
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Not yet recruiting

A Study of IMM01 Plus Tiselizumab Versus Physician's Choice Chemotherapy in PD(L)1-refractory Classical Hodgkin Lymphoma

Classic Hodgkin Lymphoma
Celgene

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma (GOLSEEK-2)

Lymphoma, Follicular

United States, Australia, Brazil, Canada, Chile, France, Germany, Italy, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
Celgene

Recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

United States, Korea, Republic of, Canada, Chile, Argentina, Australia, Austria, Brazil, Bulgaria, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Japan, Malaysia, Mexico, New Zealand, Norway, Polan... and more
National Cancer Institute (NCI)

Not yet recruiting

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Classic Follicular Lymphoma | Follicular Lymphoma With Unusual Cytological Features
Juno Therapeutics, Inc., a Bristol-Myers Squibb...
Celgene Corporation

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma

Relapsed or Refractory Follicular Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.

Recruiting

Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma

China
Genmab
AbbVie

Recruiting

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma (EPCORE™FL-2)

Follicular Lymphoma (FL)

United States, Puerto Rico, Australia, Israel, Korea, Republic of, Romania, Serbia, Spain, Taiwan
French Innovative Leukemia Organisation
Hoffmann-La Roche

Recruiting

Evaluation of Treatment by Glofitamab in Combination With Rituximab or Obinutuzumab Plus CHOP in Patients With RIchter Syndrome (GLORIFY)

Richter Syndrome

France
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

Hodgkin Lymphoma

China
Ruijin Hospital

Recruiting

A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

China
Fred Hutchinson Cancer Center
Bristol-Myers Squibb

Not yet recruiting

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Prostate Carcinoma | Stage III Prostate Cancer AJCC v8 | Prostate Small Cell Neuroendocrine Carcinoma

United States
Regeneron Pharmaceuticals

Recruiting

A Trial to Learn if Odronextamab is Safe and Well-tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Participants With Follicular Lymphoma (OLYMPIA-1)

Follicular Lymphoma (FL)

United States, Spain, Taiwan, Israel, Switzerland, Poland, Austria, Turkey, Italy, United Kingdom, Czechia, Australia, Chile
Hoffmann-La Roche

Recruiting

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma (GLOBRYTE)

Lymphoma

Korea, Republic of, United States, Spain, France, Brazil, China, Canada, Australia, Sweden, Taiwan, Italy, United Kingdom
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

Relapsed/Refractory Marginal Zone Lymphoma

China
Fred Hutchinson Cancer Center
Affini-T Therapeutics, Inc.

Recruiting

Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations

Metastatic Lung Non-Small Cell Carcinoma | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Metastatic Colorectal Adenocarcinoma | Stage IV Lung Cancer AJCC v8 | Stage IV Colorectal Cancer AJCC v8

United States
Washington University School of Medicine

Recruiting

Polatuzumab Vedotin (Pola) Plus Rituximab (R) in Patients With Post-transplant Lymphoproliferative Disorder (PTLD)

Post-transplant Lymphoproliferative Disorder

United States
The Lymphoma Academic Research Organisation

Recruiting

Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Marginal Zone Lymphoma

France
Shanghai Changzheng Hospital
RenJi Hospital; Huashan Hospital; Shanghai 6th People's Hospital; Huadong Hospital

Recruiting

A Phase 2 Clinical Trial to Evaluate Zanubrutinib Combined With BR (Bendamustine/Rituximab) Regimen in Subjects With Newly-diagnosed Waldenström's Macroglobulinemia (CZ-WM01)

Waldenström's Macroglobulinemia

China
AstraZeneca

Recruiting

A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma (TrAVeRse)

Mantle Cell Lymphoma (MCL)

Canada, Poland, United Kingdom, United States, Brazil, Spain, Australia
Fate Therapeutics

Recruiting

FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)

Relapsed/Refractory B-Cell Lymphoma

United States

Search clinical trials for: bendamustine plus rituximab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in South Africa

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations